The Market’s Discards: A Look at Pfizer and Novo Nordisk

Pfizer, once a titan, now carries the weight of unmet expectation. The echoes of pandemic profits have faded, and the share price reflects a certain…disappointment. They speak of subpar results, of a pipeline needing replenishment. But a company doesn’t simply vanish. It adapts, it retrenches, it seeks new avenues. The current price, nine times forward earnings, suggests the market has already delivered its judgment. A harsh one, perhaps, but one that offers a cautious investor an opportunity.








